Tang J, et al. - Via a cohort study of individuals from age 50 years through a total of 30 1-year decision-analytic Markov models, the researchers intended to assess the cost-effectiveness and cost-utility of population-level glaucoma screening in China. Fewer net costs and greater gain in health benefits in comparison to no screening for glaucoma [primary open angle glaucoma and primary angle closure glaucoma (PACG)] combined were predicted for the rural as well as urban China setting. Cost effectiveness of particularly labor costs, and the high risk of blindness in untreated cases and in those with PACG were observed.